Mobile
Search
Advanced search
Multi-criteria search
Who are we ?
Log in
Sign up
Français
English
Kusajili – Clinical trials directory
Result
of your search per sponsor: Bayer
Woman and Man
Between 18 years
and 99 years
Bayer
Update Il y a 4 ans
Étude ARCS-Multi : étude de phase 1b évaluant l’efficacité et la sécurité de l’anétumab ravtansine associé au cisplatine chez des patients ayant un cholangiocarcinome, associé à la gemcitabine chez des patients ayant un adénocarcinome du pancréas ou en monothérapie chez des patients ayant d’autres tumeurs solides, exprimant la mésothéline, métastatiques ou non métastatiques à un stade avancé.
Les tumeurs solides peuvent se développer dans n’importe quel tissu : peau, muqueuses, os, organes, etc. Ce sont les plus fréquentes puisqu’elles représentent 90 % des cancers humains. On distingue 2 ...
Country
France
organs
Pancréas
,
Voies biliaires
,
Tumeurs solides
Specialty
Chimiothérapie
,
Immunothérapie - Vaccinothérapie
Essai ouvert aux inclusions
More information
Woman and Man Max 99 years
Freistaat Bayern, vertreten durch Klinikum der Universität Regensburg
Update Il y a 4 ans
Prospective, randomised (using minimisation), double-blind, placebo controlled study to evaluate the safety and efficacy of human normal immunoglobulin as a prophylactic agent against infections in patients with high grade gliomas
To determine the number of infective episodes in patients with high grade gliomas during treatment with 10% intravenous immunoglobulin (Kiovig) compared with placebo (normal saline).
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Bayer Healthcare AG, D-51368 Leverkusen, Germany
Update Il y a 4 ans
Estudio de fase II, aleatorizado, doble ciego, para evaluar la eficacia y la seguridad de sorafenib comparado con placebo en pacientes con cáncer epitelial de ovario o con cáncer peritoneal primario que han alcanzado una respuesta clínica completa después de quimioterapia estándar con platino/taxano. (A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients who have achieved a Complete Clinical Response after Standard Platinum/Taxane Containing Chemotherapy)
The objective of this study is to evaluate the efficacy and safety of sorafenib compared to placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer patients who have achieved a complete clin...
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Bayer AG
Update Il y a 4 ans
Efficacy and safety of two different aflibercept regimens in subjects with nAMD
To compare the efficacy of 2 mg aflibercept administered by two different intravitreal (IVT) treatment regimens to subjects with nAMD.
Country
None
organs
None
Specialty
None
unknown
More information
Woman and Man Max 99 years
Bayer Health Centre
Update Il y a 4 ans
Treating neovascular age-related Macular degeneration with Aflibercept
Background and study aims Age-related macular degeneration (AMD) is the most common cause of vision loss in people over 50. It involves the gradual damage to a part of the eye called the macula. The m...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Bayer (China) Limited
Update Il y a 4 ans
The ACROSS-China trial
Not provided at time of registration
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Bayer HealthCare AG
Update Il y a 4 ans
A study to test the effectiveness of a tablet containing both Nifedipine and Candesartan Cilexetil in adults with high blood pressure whose blood pressure is not well controlled with tablets containing 16 mg Candesartan Cilexetil Estudio para probar la efectividad de un comprimido que contiene tanto Nifedipino como Candesartán Cilexetilo, en adultos con presión arterial alta y cuya presión arterial no está bien controlada con comprimidos que contienen Candesartán Cilexetilo 16 mg
The primary objective is to demonstrate the efficacy of two FDCs of nifedipine GITS and candesartan cilexetil compared to candesartan cilexetil monotherapy in subjects not adequately controlled on can...
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Bayer Schering Pharma AG
Update Il y a 4 ans
Randomized phase II study to investigate the efficacy, safety and tolerability of ZK 230211 (25 mg vs. 100 mg) as second-line endocrine therapy for postmenopausal women with hormone receptor-positive metastatic breast cancer
To evaluate efficacy (clinical benefit) of two doses of ZK PRA (25 mg and 100 mg) when administered once daily p.o.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman Max 99 years
Bayer HealthCare AG
Update Il y a 4 ans
Assess safety and efficacy of BAY 1002670 in subjects with uterine fibroids Evaluar la eficacia y la seguridad de BAY 1002670 en pacientes con miomas uterinos
To assess the dose-response relationship of BAY 1002670 in subjects with uterine fibroids. Evaluar la relación dosis-respuesta de BAY 1002670 en pacientes con miomas uterinos.
Country
None
organs
None
Specialty
None
Closed trial
More information
Woman and Man Max 99 years
Bayer HealthCare AG, 51368 Leverkusen, Germany
Update Il y a 4 ans
A Phase III randomized, placebo controlled, double blind trial of Sorafenib plus Erlotinib vs. Sorafenib plus placebo as First Line systemic treatment for Hepatocellular Carcinoma (HCC)
Overall Survival
Country
None
organs
None
Specialty
None
unknown
More information
Previous
1
2
3
4
5
6
7
8
9
10
Next